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ABSTRACT 
Motivation: Human adenovirus (HAdV) is a DNA virus that can cause a wide range of diseases, including respiratory and 
gastrointestinal infections, or conjunctivitis, that in immunocompetent individuals are ausually mild and self-limited. However, in 
immunosuppresed people and especially in pediatric units, HAdV infections present high morbidity and mortality. Currently there 
is no specific treatment approved against HAdV. The aim of this work was to characterize the anti-HAdV activity of 18 compounds 
that were previously selected after high-troughput screening (HTP) of a library of 1340 compounds, coming from our collaboration 
with the European initiative COSTACTION CM 1407 
Methods: We had evaluated the anti-HAdV activity of the compounds performing in vitro assays: plaque assays to calculate the 
IC50 value, citotoxicity assays to calculate the CC50 value, yield reduction assays and qPCR in real time to evaluate the inhibitory 
effect, and nucleocitoplasm assays to evaluate their mechanism of action. 
Results: It has been proven that 2 compounds, BBN75 and GSAED772E-1S2R have a safe selectivity index, a great inhibitory 
effect and they may act in steps subsequent to the arrival of the viral genome at the nucleus of the host cell.  
Conclusions: The results indicates that BBN75 and GSAED772E-1S2R are promising anti-HAdV drugs to be evaluated at in 
vivo assays. 
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